Investment case
Editas Medicine, Inc.
EDIT · 9 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 9 macro, policy, and market developments to Editas Medicine, Inc. since 2026-09-09. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for EDIT yet, so no modelled value is shown. The EDIT valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run EDIT on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.
· Moves investor perception of gene editing platform risk, ability to raise capital
- Open question
Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline
Second-order effect: Investor sentiment and competitive landscape in the gene editing and CAR T space. Positive or negative news from Cellectis could spill over to peers.
· Moves investor sentiment biotech sector, perceived risk gene editing platform
What changed, by assumption
- 2026-09-09CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
- 2026-09-09CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
- 2026-09-25Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
- 2026-09-12Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline
- 2026-09-12Cellectis Schedules September 14 Business and CAR T Pipeline Update
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million | watch | 3-12m | 0.20 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Bullish | 3-12m | 0.30 |
| 2026-09-12 | Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline | mixed | 1-3m | 0.30 |
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | watch | 1-5d | 0.30 |
| 2026-09-12 | Cellectis sets September 14 business update on CAR-T and gene editing pipeline | watch | 1-5d | 0.20 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Bullish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Bullish | 3-12m | 0.30 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Bullish | 1-3m | 0.30 |
| 2026-09-09 | CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M | Bullish | 3-12m | 0.40 |